Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BioAlliance Pharma Expands Its LoramycTM Franchise by Signing a South East Asia Deal Worth up to $12 Million with the Leading Korean Pharma Company Ha

Abstract:
BioAlliance Pharma SA (Paris:BIO) today announced that it has entered into an exclusive licensing agreement under which Korea-based Handok Pharmaceuticals will receive commercialization rights in Korea, Taiwan, Singapore and Malaysia. BioAlliance Pharma's innovative, muco-adhesive antifungal therapy Loramyc™ (miconazole Lauriad®) is already approved in Europe and a Phase III clinical trial has just completed in the United States.

BioAlliance Pharma Expands Its LoramycTM Franchise by Signing a South East Asia Deal Worth up to $12 Million with the Leading Korean Pharma Company Ha

PARIS, France | Posted on March 30th, 2008

BioAlliance Pharma's third commercial partnership is potentially worth $12 million to the Paris-based firm, including $1.5 million on signature and a further $1.5 million on first sale in Korea - the remainder being sales milestones (up to $9 million) in the designated territory and double-digit royalties commensurate with the product stage.

"Handok is the ideal partner, with good marketing capabilities for South East Asia. We are delighted to be able to introduce Loramyc to the Asian market through this company", said Dominique Costantini (BioAlliance Pharma's President and CEO) after the signing ceremony in Seoul. She added that "Handok has a longstanding relationship with major pharmaceutical companies and a track record in successfully commercializing the latter's products in this geographic zone. We shall continue our efforts to make Loramyc™ available worldwide in due course through strategic partners like Handok".

Mr. Young-jin Kim (CEO of Handok Pharmaceuticals) commented: "We are very pleased to be teaming up with BioAlliance Pharma on this innovative product, which has good efficacy and will help to improve the patients' quality of life. Handok plans to launch Loramyc™ in 2010. We expect to establish a mutually beneficial, long-term partnership with BioAlliance Pharma because this agreement opens the door to more products from both BioAlliance and the world of biotech and will contribute to Handok's continued expansion".

####

About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and infectious disease markets.

In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and the USA (with Par Pharmaceutical). For more information, visit BioAlliance Pharma's website at www.bioalliancepharma.com.

About Handok Pharmaceuticals

Handok Pharmaceuticals is a Korean-based pharma company founded in the 1950s via an alliance with Hoechst and then extended through a JV in the 1960s. In the 1970s, the company also formed a strategic alliance with Roussel Uclaf and, on the diagnostic side, with Behring. In 2000, Handok formed a new strategic partnership with Sanofi-Aventis. 2007 sales amounted to $250 million and the company also has major GMP manufacturing capabilities. Handok is well established in Korea and has established a new alliance with YSP in Taiwan. Its main product lines are in the digestive field, cardiovascular diseases and diabetes treatments. In the hospital prescription sector, Handok develops post-chemotherapy anti-emetic treatments, anti-infectives and haematological treatments.

For more information, visit the Handok website at www.handok.co.kr.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6 2007 under the number R. 07-031, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
+33 1 45 58 76 01
President and CEO

or
Nicolas Fellmann, CFO
+33 1 45 58 71 00

or
ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Shape matters when light meets atom: Mapping the interaction of a single atom with a single photon may inform design of quantum devices December 4th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Nanomedicine

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016

Announcements

Shape matters when light meets atom: Mapping the interaction of a single atom with a single photon may inform design of quantum devices December 4th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Novel Electrode Structure Provides New Promise for Lithium-Sulfur Batteries December 3rd, 2016

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Alliances/Trade associations/Partnerships/Distributorships

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Mechanism for sodium storage in 2-D material: Tin selenide is an effective host for storing sodium ions, making it a promising material for sodium ion batteries October 27th, 2016

Enterprise In Space Partners with Sketchfab and 3D Hubs for NewSpace Education October 13th, 2016

Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B October 6th, 2016

New-Contracts/Sales/Customers

Cetim Facility Receives Bruker Contour CMM Dimensional Analysis System: New Optical Coordinate Measurement Technology Enables High-Precision 3D Scanning November 16th, 2016

Industrial Nanotech, Inc. Announces Plans to Spin Off New Product Line to Major Paint Compan November 9th, 2016

Leti Provides New Low-noise Image Technology to French SME PYXALIS; Will Be Demonstrated at Vision 2016 in Stuttgart November 3rd, 2016

DryWired's Liquid Nanotint to be the first nano-insulation in a Federal building: 250,000 federal buildings, most with uninsulated glass October 12th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project